Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With Palivizumab
- 1 October 2004
- journal article
- editorial
- Published by American Academy of Pediatrics (AAP)
- Vol. 114 (4) , 1082-1084
- https://doi.org/10.1542/peds.2004-1300
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Deaths among children less than two years of age receiving palivizumab: an analysis of comorbiditiesThe Pediatric Infectious Disease Journal, 2004
- Advances in the laboratory diagnosis of viral respiratory diseaseThe Pediatric Infectious Disease Journal, 2004
- Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus InfectionsPediatrics, 2003
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Substantial variability in community respiratory syncytial virus season timingThe Pediatric Infectious Disease Journal, 2003
- Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usageThe Pediatric Infectious Disease Journal, 2003
- Guidelines for Quality Standards for ImmunizationClinical Infectious Diseases, 2002
- Bronchiolitis-Associated Hospitalizations Among US Children, 1980-1996JAMA, 1999
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1997